Categories: News

Rapid Micro to Announce Third Quarter 2021 Financial Results on November 11, 2021

Conference Call to Discuss Results on November 12, 2021 at 5:00am Pacific Time/8:00am Eastern Time

LOWELL, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (“Rapid Micro” or the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that it will release financial results for the third quarter of 2021 after market close on Thursday, November 11, 2021.

Conference Call Details

Company management will host a webcast conference call to discuss third quarter 2021 financial results beginning at 5:00am Pacific Time/8:00am Eastern Time on Friday, November 12, 2021. The conference call will be available to interested parties via live webcast on the Company’s website at https://investors.rapidmicrobio.com/. The webcast will then be archived and available for replay for at least 90 days following the event.

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct® System automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct® System brings the quality control lab to the manufacturing floor, unlocking the power of in-line/at-the-line MQC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making, that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on Twitter at @rapidmicrobio or on LinkedIn.

CONTACT: Investor Contact:
David Deuchler
Gilmartin Group LLC
investors@rapidmicrobio.com

Media Contact:
media@rapidmicrobio.com

Staff

Recent Posts

Establishment Labs Submits to FDA for Approval of Motiva Implants in Breast Reconstruction

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to…

2 hours ago

Establishment Labs Submits to FDA for Approval of Motiva Implants in Breast Reconstruction

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to…

2 hours ago

Adia Nutrition Inc. Recaps Transformative 2025: Explosive Growth, Strategic Focus, and Path to Nasdaq Uplisting

Winter Park, Florida--(Newsfile Corp. - December 29, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a…

2 hours ago

Changing Healthcare Trajectories With Positive Experiences

DaVita works with others in under-resourced communities to offer individualized health engagements, break down mistrust…

2 hours ago

Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On

PONTE VEDRA, FL / ACCESS Newswire / December 29, 2025 / Every industry has its…

2 hours ago

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

Contract Research Organization for the REGAL trial has informed the Company that 72 events have…

2 hours ago